Trial Profile
A Phase 3, Multi-Center, Randomized, Double-Masked, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of SkQ1 Ophthalmic Solution for the Treatment of Dry Eye Syndrome
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 03 May 2022
Price :
$35
*
At a glance
- Drugs Plastoquinonyl-decyl-triphenylphosphonium (Primary)
- Indications Dry eyes
- Focus Registrational; Therapeutic Use
- Acronyms VISTA-1
- Sponsors Mitotech
- 28 Apr 2022 According to a Ora Inc media release, data from VISTA-1 and VISTA-2 studies will be presented at the Association for Research in Ophthalmology Conference (ARVO), 2022.
- 26 Feb 2021 Results presented in a Mitotech media release.
- 12 Dec 2019 Primary endpoint has not been met. (Grittiness change from baseline), according to a Mitotech media release.